Gemcitabine: a game changer in nasopharyngeal carcinoma

Affiliations

¹ Division of Radiation Oncology, National Cancer Centre Singapore 169610, Singapore, Singapore; Duke-NUS Graduate Medical School, Singapore, Singapore. Electronic address: melvin.chua.l.k@nccs.com.sg.
² State Key Laboratory of Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China.

Comment

Melvin L K Chua et al. Lancet. 2016.

. 2016 Oct 15;388(10054):1853-1854.

doi: 10.1016/S0140-6736(16)31394-0. Epub 2016 Aug 23.

¹ Division of Radiation Oncology, National Cancer Centre Singapore 169610, Singapore, Singapore; Duke-NUS Graduate Medical School, Singapore, Singapore. Electronic address: melvin.chua.l.k@nccs.com.sg.
² State Key Laboratory of Oncology in South China, Sir Y K Pao Centre for Cancer, Department of Clinical Oncology, Hong Kong Cancer Institute, The Chinese University of Hong Kong, Hong Kong, China.

No abstract available

Comment on

Gemcitabine plus cisplatin versus fluorouracil plus cisplatin in recurrent or metastatic nasopharyngeal carcinoma: a multicentre, randomised, open-label, phase 3 trial.
Zhang L, Huang Y, Hong S, Yang Y, Yu G, Jia J, Peng P, Wu X, Lin Q, Xi X, Peng J, Xu M, Chen D, Lu X, Wang R, Cao X, Chen X, Lin Z, Xiong J, Lin Q, Xie C, Li Z, Pan J, Li J, Wu S, Lian Y, Yang Q, Zhao C. Zhang L, et al. Lancet. 2016 Oct 15;388(10054):1883-1892. doi: 10.1016/S0140-6736(16)31388-5. Epub 2016 Aug 23. Lancet. 2016. PMID: 27567279 Clinical Trial.